Hodi et al. showed that first-line nivolumab combined with ipilimumab or nivolumab alone in patients with advanced melanoma, regardless of BRAF mutation status, could obtain long-lasting, sustained clinical benefits [103]. This evidence concerns the gene BRAF and melanoma.